Roche has hosted the grand opening of the Roche Genentech Innovation Center Boston, expanding Roche and Genentech’s US research presence in one of the world’s leading life sciences communities.
Located at Harvard’s Enterprise Research Campus in Allston, the Roche Genentech Innovation Center Boston will serve as Roche’s Cardiovascular, Renal and Metabolism (CVRM) hub, establishing a significant end-to-end research and deveopment presence in CVRM.
With the new site, Roche and Genentech are expanding their footprint within the Greater Boston innovation ecosystem, leveraging local talent and anchoring an entrepreneurial hub at Harvard’s Enterprise Research Campus. It brings together scientists from across discovery research, clinical development, artificial intelligence and data science disciplines, and creates an end-to-end research environment spanning early-stage discovery through late-stage clinical development.
The Innovation Center is part of Roche and Genentech’s investment commitment in US manufacturing and R&D and builds on recent investments and manufacturing milestones in Holly Springs, North Carolina, and Hillsboro, Oregon. Together, these investments expand an end-to-end US footprint spanning research, development and manufacturing and reflect the companies’ long-term commitment to American scientific innovation. Roche and Genentech have around 25,000 employees in the United States, with 15 R&D centres and 13 manufacturing sites across Pharma and Diagnostics.
Thomas Schinecker, CEO Roche Group, commented: “Scientific innovation has always been the foundation of Roche and Genentech’s success, and the United States remains one of our most important innovation hubs. This investment in Boston is an important part of our commitment to expand our US manufacturing and R&D footprint. By investing in scientific talent, new capabilities and infrastructure, we are strengthening our ability to discover and develop the next generation of medicines for patients.”
This new investment highlights Roche's dedication to advancing healthcare through academic and scientific collaboration in Boston’s life sciences ecosystem. These drug discovery efforts have included work to combat antibiotic resistant bacteria as well as the use of AI in cancer research to identify targeted approaches to treatment and to analyse the effectiveness of new cancer drugs in clinical trials.
Roche and Genentech have signed a 10-year lease for the 95,000 square metre building, which will have capacity for up to 500 people across research, clinical development, data science and other areas.